查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004827

介入性神经外科医疗设备市场：依产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Interventional Neurology Devices Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，介入性神经医疗设备市场价值将达到 23.8 亿美元，到 2026 年将成长至 26.2 亿美元，到 2032 年将达到 44.8 亿美元，复合年增长率为 9.44%。

主要市场统计数据
基准年 2025 23.8亿美元
预计年份：2026年 26.2亿美元
预测年份 2032 44.8亿美元
复合年增长率 (%) 9.44%

这本权威的入门书籍说明了设备类别、临床应用和操作技术与现代护理路径和相关人员决策标准之间的关係。

介入性神经外科器械处于快速临床创新和不断发展的医疗服务流程的交汇点，这不仅为临床医生、医院管理者和医疗技术开发人员带来了机会，也带来了挑战。本报告首先概述了关键器械类别及其临床应用和手术流程，然后建立了一个框架，阐述如何将各项技术整合到脑血管疾病的治疗流程中。报告强调了器械的连续性，从栓塞器和血流灌注系统到先进的弹簧圈、支架和血栓切除平台，并说明如何在手术团队和影像环境中优化这些器械的使用。

设备创新、临床证据的成熟以及医疗保健服务体系的重组，是如何重新定义神经血管照护的治疗方法和实施趋势的？

由于技术进步、临床证据日趋成熟以及医疗服务模式的重组，介入神经病学领域正经历变革性的转变。近年来，血流灌注平台的进步，以及线圈配置和支架设计的不断改进，重新定义了复杂动脉瘤的治疗阈值，并扩大了血管内治疗的选择范围。同时，血栓除去装置的改进，特别是抽吸导管和血栓摘取支架的改进，提高了急性缺血性脑中风的治疗标准。手术流程的改进体现在器械设计、导管相容性以及辅助系统的整合等方面。

本研究评估了近期关税变化和贸易政策转变对医疗设备供应链和医院采购行为的广泛运作、采购和购买影响。

美国政策的转变和关税调整正对介入性神经病学器械生态系统产生重大影响，波及供应链经济、筹资策略和国际采购决策。某些医疗设备组件和原料关税的提高，增加了依赖跨境供应链的製造商的投入成本。这种压力促使企业更加严格地审查供应商合同，加快供应商多元化策略的实施，并重新评估库存管理实践，以降低贸易相关的成本波动风险。

将产品差异化、临床应用需求、技术基础和最终用户优先事项与部署和商业化方案连结起来的实用细分见解。

精细化的细分观点揭示了不同产品类型、临床应用、技术平台和终端用户环境之间的差异，这些差异共同塑造了医疗设备製造商和医疗保健系统的策略重点。在产品类型中，创新路径也各不相同。栓塞剂正朝向液体栓塞剂、微球和颗粒剂等多种方向发展，以实现个人化的栓塞方案。同时，血流导向装置也不断演进，形成诸如Fred、Pipeline装置和Surpass Streamline等差异化平台，每种平台在输送能力和孔隙率方面都存在差异。神经血管弹簧圈的材料也日益多样化，生物活性弹簧圈和水凝胶增强弹簧圈与传统的铂金弹簧圈相比，能够提供不同的癒合反应。支架结构也朝着球囊扩张型和自扩张式设计发展，以适应不同的解剖结构和手术操作。从操作角度来看，血栓除去装置可分为抽吸导管系统和血栓摘取支架，每种类型都会影响手术流程和影像需求。

区域法规结构、临床基础设施成熟度和製造生态系统如何塑造全球主要市场中差异化的部署模式？

区域趋势对器材研发、监管策略和临床应用模式有着显着影响，美洲、欧洲、中东、非洲和亚太地区呈现出各自独特的市场驱动因素。在美洲，完善的急性卒中诊疗网络、先进的影像基础设施以及集中于综合医疗体系中的强大采购能力，正在加速最先进的血栓切除术和血流逆转器械的应用；同时，供应链因素和报销环境也影响着采购週期和应用速度。该地区的临床研究网络和註册登记系统有助于快速产生循证医学证据，从而支持器械的迭代改进和指南的纳入。

以整合平台、证据产生和协作商业化为优先的策略性企业行动和竞争定位，以推动永续的临床应用。

介入性神经病学领域的竞争动态取决于对研发的持续投入、策略伙伴关係以及以临床实践为导向的项目，这些因素共同推动了产品差异化和平台演进。主要企业大力投资于优化器械输送性能、材料科学和平台互通性，同时积极开展有针对性的临床研究和真实世界数据（REW）项目，以支持其性能声明。与学术机构和神经血管註册中心的合作能够提供关键数据，支持扩大适应症范围和指南采纳，从而增强临床医生的信心并提升医院采购委员会的评估水平。

为製造商、医疗保健系统和临床领导者提供切实可行的优先建议，以协调证据、供应弹性和商业化，从而实现永续应用。

行业领导者应优先考虑一系列务实倡议，使产品开发、商业性合作和营运韧性与不断变化的临床和政策现实相契合。首先，应投资建立健全的临床证据项目，涵盖纵向结果、病患报告结果和卫生经济学分析，这些分析应能引起医院负责人和支付方决策者的共鸣，而不仅限于急性治疗指标。此外，还应利用可操作的註册数据和真实世界绩效报告来补充临床试验，从而加速指南的采纳和支付方的核准。

混合方法研究框架，结合临床医生和采购负责人的初步见解与系统的二次分析，得出稳健且可重复的结论。

本研究将采用混合方法，以与关键相关人员的互动和严谨的二手资料研究为核心，整合多方面的证据，建构神经介入医疗设备环境的全面图景。主要资讯来源包括对临床意见领袖、介入医师、医院采购经理和医疗设备研发专家的资讯来源，以获取关于手术趋势、医疗设备性能预期和医疗保健优先事项的第一手观点。此外，还将收集来自手术团队的匿名调查数据，检验不同医疗机构中医疗设备的选择模式和使用趋势，从而补充上述定性研究。

对临床、营运和政策趋势进行简洁、全面的分析，重点在于加速设备普及和维持临床影响的统一优先事项。

总而言之，介入性神经外科器械正处于临床创新、供应链复杂性和医疗服务模式变革的快速交汇点，所有这些因素共同决定了製造商、医疗服务提供者和支付方的策略重点。从栓塞剂和弹簧圈材料到先进的血流导引平台和血栓切除系统，器械的发展轨迹表明，材料科学、器械工程和手术流程如何协同演进，以改善患者预后。同时，贸易政策趋势和关税相关压力凸显了具有韧性的筹资策略和灵活的商业性安排的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 介入性神经医疗设备市场：依产品类型划分

  • 栓塞剂
    • 液态栓塞剂
    • 微球
    • 颗粒栓子
  • 血液灌流装置
    • Fred
    • 管道装置
    • 超越流线型
  • 神经血管线圈
    • 生物活性线圈
    • 水凝胶线圈
    • 铂金线圈
  • 神经血管支架
    • 球囊扩张型支架
    • 自动扩张型支架
  • 血栓除去装置
    • 吸痰管
    • 血栓摘取支架

第九章 介入性神经医疗设备市场：依技术划分

  • 导管导引线系统
    • 亲水涂层
    • 聚合物涂层
  • 机械血栓切除术
  • 微导管系统
    • 导丝引导式微导管
    • 快速交换微导管
  • 溶栓剂
    • tpa
    • 尿激酶

第十章 介入性神经医疗设备市场：依应用领域划分

  • 动脉瘤
  • 动静脉畸形
  • 颈动脉狭窄
  • 缺血性中风
  • 血管痉挛

第十一章 介入性神经医疗设备市场：依最终用户划分

  • 门诊手术中心
  • 诊断影像中心
  • 医院
  • 介入神经放射学诊所

第十二章 介入性神经医疗设备市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 介入性神经医疗设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 介入性神经医疗设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国介入性神经医疗设备市场

第十六章：中国介入神经医疗设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Acandis GmbH
  • B. Braun Melsungen AG
  • Balt USA LLC
  • Boston Scientific Corporation
  • Cerus Endovascular Ltd.
  • Integer Holdings Corporation
  • Integra LifeSciences Holdings Corporation
  • Johnson & Johnson Services, Inc.
  • Medos SA
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • MicroVention, Inc.
  • Penumbra, Inc.
  • Rapid Medical
  • Stryker Corporation
  • Terumo Corporation
Product Code: MRR-742BD517FEBA

The Interventional Neurology Devices Market was valued at USD 2.38 billion in 2025 and is projected to grow to USD 2.62 billion in 2026, with a CAGR of 9.44%, reaching USD 4.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.38 billion
Estimated Year [2026] USD 2.62 billion
Forecast Year [2032] USD 4.48 billion
CAGR (%) 9.44%

An authoritative introduction that maps device categories, clinical applications, and procedural technologies to contemporary care pathways and stakeholder decision criteria

Interventional neurology devices are at the intersection of rapid clinical innovation and evolving care delivery pathways, creating both opportunity and complexity for clinicians, hospital administrators, and medical technology developers. This report initiates with a focused overview that situates core device categories alongside clinical applications and procedural workflows, framing how distinct technologies integrate into treatment algorithms for cerebrovascular disease. Emphasis is placed on the continuum of devices, from embolic agents and flow diversion systems to advanced coils, stents, and thrombectomy platforms, and how these instruments are optimized within procedural teams and imaging environments.

In parallel, the introduction outlines how device-specific innovations such as liquid embolics, microspheres, and particulate embolics have influenced therapeutic choices for aneurysm and arteriovenous malformation interventions, while flow diversion devices including high-profile platforms have altered the approach to complex aneurysm management. The narrative also recognizes the differential roles of neurovascular coils-ranging from bioactive and hydrogel variants to traditional platinum coils-and the technical distinctions between balloon-expandable and self-expanding stent designs. The thrombectomy armamentarium, including aspiration catheters and stent retrievers, is positioned within acute ischemic stroke pathways, underscoring the time-sensitive nature of device performance.

Finally, the introductory section sets expectations for the report's analytical scope by describing how device categories interact with application areas such as aneurysm, arteriovenous malformations, carotid stenosis, ischemic stroke, and vasospasm. It explains how advances in guidewire systems, microcatheter platforms, mechanical thrombectomy techniques, and thrombolytic agents underpin procedural success, and how end users across ambulatory surgical centers, diagnostic imaging centers, hospitals, and specialized neuro interventional clinics shape adoption dynamics. This framing prepares readers for detailed downstream analysis of regulatory, clinical, economic, and operational factors that drive strategic choices across the ecosystem.

How converging device innovation, clinical evidence maturation, and care-delivery reconfiguration are redefining therapeutic approaches and adoption dynamics across neurovascular practice

The interventional neurology landscape is undergoing transformative shifts driven by converging technological advancements, clinical evidence maturation, and reconfigured care delivery models. Over recent years, the increasing refinement of flow diversion platforms-alongside iterative improvements in coil composition and stent design-has redefined therapeutic thresholds for complex aneurysms and expanded endovascular options. Concurrent enhancements in thrombectomy devices, specifically aspiration catheters and stent retrievers, have elevated the standard of care in acute ischemic stroke, with procedural refinements reflected in device design, catheter compatibility, and ancillary system integration.

Technological progress is complemented by advances in supporting systems such as guidewire variants with hydrophilic or polymer coatings, refined microcatheter architectures including over-the-wire and rapid-exchange designs, and evolving thrombolytic agents like tPA and urokinase that influence adjunctive strategies. These innovations are reshaping procedural workflows and prompting multidisciplinary teams to reassess training, imaging protocols, and peri-procedural care. Meanwhile, adoption patterns are shifting as care migrates beyond traditional hospital interventional suites to ambulatory surgical centers and specialized neuro interventional clinics that prioritize throughput, patient experience, and cost optimization.

Regulatory landscapes and payer policies are adapting to new evidence and real-world data collection, catalyzing a stronger focus on value demonstration and longitudinal outcomes. At the same time, manufacturers are pursuing portfolio consolidation and modular platform strategies to provide end-to-end procedural solutions. Taken together, these forces are producing a dynamic environment in which clinical efficacy, device interoperability, and care-delivery economics jointly determine successful product adoption and long-term clinical integration.

Evaluating the broad operational, sourcing, and procurement consequences of recent tariff changes and trade policy shifts on device supply chains and hospital purchasing behaviors

Policy shifts and tariff adjustments in the United States have material implications for the interventional neurology device ecosystem, impacting supply chain economics, procurement strategies, and international sourcing decisions. Increased tariffs on certain medical device components and raw materials elevate input costs for manufacturers who depend on cross-border supply chains. This pressure translates into heightened scrutiny of supplier contracts, an acceleration of supplier diversification strategies, and a reassessment of inventory management practices to mitigate exposure to trade-related cost volatility.

Manufacturers and distributors respond by accelerating localization and nearshoring initiatives where feasible, expanding dual-sourcing arrangements, and renegotiating commercial terms to preserve margins while maintaining competitive pricing for hospitals and imaging centers. Hospitals and ambulatory surgical centers, mindful of constrained budgets, intensify procurement diligence and prioritize devices supported by robust clinical data and predictable lifecycle costs. As a result, there is increased emphasis on total cost of ownership analyses, long-term service agreements, and arrangements that bundle consumables with device platforms to achieve price stability.

Clinicians and hospital administrators also adjust procurement timelines and capital planning to accommodate lead-time variability and potential tariff-related cost adjustments. Regulatory and compliance teams must remain vigilant to ensure that device modifications or supplier changes do not inadvertently affect regulatory status or clinical labeling. Finally, payers and health systems may scrutinize unit pricing and reimbursement pathways more closely, driving manufacturers to emphasize outcomes-based evidence and align commercial models with performance metrics that resonate with value-driven stakeholders.

Actionable segmentation insights that connect product differentiation, clinical application demands, technology enablers, and end-user priorities to implementation and commercialization choices

A granular segmentation lens reveals distinct dynamics across product types, clinical applications, technology platforms, and end-user settings that collectively shape strategic priorities for device manufacturers and health systems. Within product categories, differential innovation trajectories are evident: embolic agents have diversified into liquid embolics, microspheres, and particulate options that enable tailored embolization profiles, while flow diversion devices have evolved into differentiated platforms such as Fred, Pipeline devices, and Surpass streamlines that vary in deliverability and porosity. Neurovascular coils demonstrate material-driven differentiation with bioactive and hydrogel-enhanced coils offering distinct healing responses compared with traditional platinum coils, and stent architectures split between balloon-expandable and self-expanding designs to accommodate anatomical and procedural variability. Thrombectomy devices divide operationally between aspiration catheter systems and stent retrievers, each influencing procedural workflow and imaging requirements.

Application-based segmentation highlights how device choice aligns tightly to clinical goals. Aneurysm treatment prioritizes device conformability and long-term vessel remodeling, arteriovenous malformation interventions require precise embolic control, carotid stenosis management balances hemodynamic restoration with embolic protection, ischemic stroke care is dominated by time-to-revascularization imperatives, and vasospasm therapies emphasize targeted delivery and vessel-sparing profiles. Technology segmentation underscores the role of ancillary systems in enabling successful procedures: guidewire systems with hydrophilic or polymer coatings affect maneuverability, mechanical thrombectomy techniques demand compatible catheter and stent designs, microcatheter system variations influence crossing strategies and device deployment options, and thrombolytic agents such as tPA and urokinase remain central to adjunctive pharmacologic protocols.

End-user segmentation illuminates the influence of care settings on device adoption and utilization patterns. Ambulatory surgical centers and neuro interventional clinics often prioritize devices that optimize turnover, reduce anesthesia requirements, and simplify inventory, while diagnostic imaging centers and hospitals focus on integrated solutions that support complex case mixes and robust post-procedural monitoring. Understanding these segmentation interdependencies enables more precise targeting of clinical evidence generation, training programs, and commercial engagement models that resonate with specific procedural contexts and budgetary constraints.

How regional regulatory frameworks, clinical infrastructure maturity, and manufacturing ecosystems are shaping differentiated adoption patterns across major global markets

Regional dynamics exert substantial influence on device development, regulatory strategy, and clinical adoption patterns, with distinct market drivers apparent across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, robust acute stroke networks, advanced imaging infrastructure, and concentrated purchasing power among integrated health systems accelerate uptake of cutting-edge thrombectomy systems and flow diversion devices, while supply chain considerations and reimbursement environments shape procurement cycles and adoption pacing. Clinical research networks and registries in this region facilitate rapid evidence generation that supports iterative device improvements and guideline incorporation.

Europe, the Middle East & Africa present heterogeneous regulatory environments and reimbursement systems that require modular market entry strategies. Regulatory convergence across certain European jurisdictions simplifies some aspects of approval, but country-level reimbursement pathways and hospital procurement practices necessitate tailored value demonstration and local evidence generation. In parts of the Middle East and Africa, infrastructure constraints and workforce training needs influence the pace of adoption, creating opportunities for solutions that emphasize simplified workflows and robust clinical support.

Asia-Pacific is characterized by diverse adoption profiles driven by demographic trends, rising investment in stroke care pathways, and substantial manufacturing capacity. Several markets within the region present strong device manufacturing ecosystems and opportunities for collaborative innovation, while others prioritize cost-effective solutions compatible with constrained budgets. Across the region, rapid expansion of diagnostic imaging capabilities and growing emphasis on interventional neuroradiology training programs are important enablers of broader device utilization. Recognizing these regional distinctions is essential for designing regulatory strategies, clinical studies, and commercial partnerships that align with local system priorities.

Strategic corporate behaviors and competitive positioning that prioritize integrated platforms, evidence generation, and collaborative commercialization to drive durable clinical adoption

Competitive dynamics in interventional neurology are defined by a combination of sustained investment in R&D, strategic partnerships, and focused clinical engagement programs that drive product differentiation and platform evolution. Leading firms invest heavily to optimize device deliverability, material science, and platform interoperability, while pursuing targeted clinical studies and real-world evidence initiatives to substantiate performance claims. Collaborations with academic centers and neurovascular registries provide pivotal data that inform label expansions and guideline recognition, reinforcing clinician confidence and hospital purchasing committees' assessments.

In addition to organic product development, companies are actively pursuing portfolio rationalization and selective acquisitions to fill technology gaps-particularly where ancillary systems such as guidewires, microcatheters, and aspiration platforms create integrated solution opportunities. Distribution strategies are evolving to include direct engagement with large health systems, partnerships with specialist distributors for regional reach, and the development of training and proctoring programs to accelerate adoption. Service offerings that combine device supply with digital procedural analytics, long-term follow-up tools, and education pathways are emerging as differentiators that enhance provider loyalty and facilitate broader clinical uptake.

Finally, firms that demonstrate agility in responding to supply chain pressures, regulatory changes, and reimbursement complexity gain competitive advantage. Those that invest in transparent outcomes reporting and payer-engaged value frameworks position themselves to navigate pricing pressures and procurement scrutiny more effectively, while simultaneously reinforcing clinical credibility through sustained engagement with key opinion leaders and multidisciplinary treatment teams.

Practical and prioritized recommendations for manufacturers, health systems, and clinical leaders to align evidence, supply resilience, and commercialization for sustainable adoption

Industry leaders should prioritize a set of actionable initiatives that align product development, commercial engagement, and operational resilience with evolving clinical and policy realities. First, invest in robust clinical evidence programs that move beyond acute procedural metrics to encompass longitudinal outcomes, patient-reported measures, and health economics analyses that resonate with hospital procurement and payer decision-makers. Complement clinical trials with pragmatic registry data and real-world performance reporting to accelerate guideline inclusion and payer recognition.

Second, strengthen supply chain resilience by diversifying suppliers, implementing dual-sourcing strategies for critical components, and evaluating selective nearshoring opportunities to mitigate tariff and trade volatility. Establish clear inventory governance and collaborative forecasting arrangements with major health system customers to reduce lead-time risk. Third, design commercialization models that offer modular value propositions tailored to specific end users: packaged clinical support and training for ambulatory surgical centers, integrated platform solutions for high-volume hospitals, and targeted outreach for diagnostic imaging centers that support multidisciplinary workflows.

Fourth, prioritize interoperability and ease of use by harmonizing device interfaces with common imaging and navigation systems, while investing in digital support tools that enhance procedural planning and post-procedural follow-up. Finally, cultivate payer engagement strategies that emphasize outcomes-based approaches and total cost of care benefits, enabling negotiations that reflect device value in clinical pathways and support sustainable adoption across diverse healthcare settings.

A mixed-methods research framework combining primary clinician and procurement insights with systematic secondary analysis to ensure robust, reproducible conclusions

This research synthesizes multiple evidence streams to construct a comprehensive view of the interventional neurology device environment, leveraging a mixed-methods approach centered on primary stakeholder engagement and rigorous secondary analysis. Primary inputs include structured interviews with clinical thought leaders, interventionalists, hospital procurement executives, and device development experts to capture firsthand perspectives on procedural trends, device performance expectations, and institutional priorities. These qualitative engagements are supplemented by anonymized survey data from procedural teams to validate patterns of device selection and usage dynamics across different care settings.

Secondary research incorporates systematic review of peer-reviewed clinical literature, procedural registries, regulatory filings, and publicly available health system procurement documentation to ensure findings are grounded in documented clinical outcomes and policy contexts. Supply chain mapping and component sourcing analysis are conducted through supplier interviews and customs data review to identify exposure points and mitigation strategies. Triangulation across information sources is used to reconcile inconsistencies and strengthen confidence in thematic conclusions. Where appropriate, sensitivity analyses and scenario planning exercises are employed to explore the operational implications of policy shifts and technology adoption pathways.

Ethical standards and data privacy considerations governed the study's primary research activities, ensuring that interview and survey participants provided consent and that data were anonymized prior to analysis. The methodology emphasizes transparency and reproducibility by documenting data sources, interview protocols, and analytical frameworks available within the technical appendix for purchaser review.

A concise synthesis of clinical, operational, and policy dynamics that underscores the integrated priorities for advancing device adoption and sustaining clinical impact

In conclusion, interventional neurology devices occupy a rapidly evolving nexus of clinical innovation, supply chain complexity, and shifting care-delivery models that together dictate strategic priorities for manufacturers, providers, and payers. The trajectory of device development-from embolic agents and coil materials to advanced flow diversion platforms and thrombectomy systems-illustrates how material science, device engineering, and procedural technique co-evolve to improve patient outcomes. At the same time, trade policy dynamics and tariff-related pressures underscore the importance of resilient sourcing strategies and flexible commercial arrangements.

Strategic success in this environment depends on integrating rigorous clinical evidence generation with pragmatic supply chain planning and tailored commercialization approaches that respect the heterogeneity of end-user settings. Regional nuances in regulatory regimes, infrastructure maturity, and manufacturing capacity require bespoke market-entry and clinical engagement plans. Ultimately, stakeholders that align product innovation with demonstrable outcomes, transparent value propositions, and operational reliability will be best positioned to support clinicians in delivering advanced neurovascular care while navigating economic and policy headwinds.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Interventional Neurology Devices Market, by Product Type

  • 8.1. Embolic Agents
    • 8.1.1. Liquid Embolics
    • 8.1.2. Microspheres
    • 8.1.3. Particulate Embolics
  • 8.2. Flow Diversion Devices
    • 8.2.1. Fred
    • 8.2.2. Pipeline Devices
    • 8.2.3. Surpass Streamlines
  • 8.3. Neurovascular Coils
    • 8.3.1. Bioactive Coils
    • 8.3.2. Hydrogel Coils
    • 8.3.3. Platinum Coils
  • 8.4. Neurovascular Stents
    • 8.4.1. Balloon-Expandable Stents
    • 8.4.2. Self-Expanding Stents
  • 8.5. Thrombectomy Devices
    • 8.5.1. Aspiration Catheters
    • 8.5.2. Stent Retrievers

9. Interventional Neurology Devices Market, by Technology

  • 9.1. Guidewire Systems
    • 9.1.1. Hydrophilic Coated
    • 9.1.2. Polymer Coated
  • 9.2. Mechanical Thrombectomy
  • 9.3. Microcatheter Systems
    • 9.3.1. Over The Wire Microcatheters
    • 9.3.2. Rapid Exchange Microcatheters
  • 9.4. Thrombolytic Agents
    • 9.4.1. Tpa
    • 9.4.2. Urokinase

10. Interventional Neurology Devices Market, by Application

  • 10.1. Aneurysm
  • 10.2. Arteriovenous Malformations
  • 10.3. Carotid Stenosis
  • 10.4. Ischemic Stroke
  • 10.5. Vasospasm

11. Interventional Neurology Devices Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospital
  • 11.4. Neuro Interventional Clinics

12. Interventional Neurology Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Interventional Neurology Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Interventional Neurology Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Interventional Neurology Devices Market

16. China Interventional Neurology Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Acandis GmbH
  • 17.7. B. Braun Melsungen AG
  • 17.8. Balt USA LLC
  • 17.9. Boston Scientific Corporation
  • 17.10. Cerus Endovascular Ltd.
  • 17.11. Integer Holdings Corporation
  • 17.12. Integra LifeSciences Holdings Corporation
  • 17.13. Johnson & Johnson Services, Inc.
  • 17.14. Medos SA
  • 17.15. Medtronic plc
  • 17.16. Merit Medical Systems, Inc.
  • 17.17. MicroPort Scientific Corporation
  • 17.18. MicroVention, Inc.
  • 17.19. Penumbra, Inc.
  • 17.20. Rapid Medical
  • 17.21. Stryker Corporation
  • 17.22. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 251. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. G7 INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. G7 INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)